Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy

Inclusion Criteria: * Patients with vitreomacular traction maculopathy for whom vitrectomy is indicated, according to the principal investigator, including: * Macular edema associated with vitreomacular traction (DME, VMTS); * Stage II-III macular hole of \< 6 months duration since symptom onset; * Demonstration of vitreomacular adhesion (based on preoperative optic coherence tomography \[OCT\]) in the study eye; * OCT - presence of posterior hyaloid membrane inserting on to the macula, but with some area of clear separation visible between the retina and the posterior hyaloid. Exclusion Criteria: * Evidence of fibrocellular proliferation characterized by whitish epimacular tissue (surface wrinkling is not an exclusion criterion). * Patients with vitreous hemorrhage which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiogram in the study eye. * Patients with rhegmatogenous retinal detachment, proliferative vitreoretinopathy (PVR), or retinal degenerative changes in the study eye. * Patients with high myopia or aphakia in the study eye * Patients with history of rhegmatogenous retinal detachment in the fellow eye or family history of retinal detachment * Patients who are considered likely to require intraocular surgery in the study eye for any reason other than vitreomacular traction maculopathy/macular edema in the coming three months. * Patients who have had ocular surgery in the study eye in the prior three months. * Patients who have had a vitrectomy in the study eye at any time. * Patients with a history of uveitis or significant trauma in the study eye. * Patients who are currently being treated for glaucoma in the study eye. * Patients who have had laser photocoagulation treatment in the study eye in the previous 3 months. * Intravitreal injection of any drug in the study eye in the previous 6 months or during the study. * Patients who are pregnant or of child-bearing potential not utilizing a form of contraception acceptable to the investigator. * Patients who, in the investigator's view, will not complete all visits and investigations, including the exit visit at 6 months. * Patients who have participated in an investigational drug study within the past 30 days. * HgA1c \> 9%. * Patients with hypertension (either systolic blood pressure \[SBP\] \> 170 or diastolic blood pressure \[DBP\] \> 100 mm Hg). * Patients with a life-expectancy less than 6 months. * Patients who have previously participated in this trial.